Get 20M+ Full-Text Papers For Less Than $1.50/day. Subscribe now for You or Your Team.

Learn More →

Impact of Chemotherapy Sequencing on Local-Regional Failure Risk in Breast Cancer Patients Undergoing Breast-Conserving Therapy

Impact of Chemotherapy Sequencing on Local-Regional Failure Risk in Breast Cancer Patients... FEATURE Impact of Chemotherapy Sequencing on Local-Regional Failure Risk in Breast Cancer Patients Undergoing Breast-Conserving Therapy ∗ ∗ Elizabeth A. Mittendorf, MD, Thomas A. Buchholz, MD,† Susan L. Tucker, PhD,‡ Funda Meric-Bernstam, MD, ∗ ∗ ∗ Henry M. Kuerer, MD, PhD, Ana M. Gonzalez-Angulo, MD,§ Isabelle Bedrosian, MD, Gildy V. Babiera, MD, ∗ ∗ Karen Hoffman, MD,† Min Yi, MD, PhD, Merrick I. Ross, MD, Gabriel N. Hortobagyi, MD,† and Kelly K. Hunt, MD uring the past several decades, significant advances have been Objective: This study was performed to evaluate long-term local-regional D made in local-regional therapy for breast cancer. The use of control rates after breast-conserving therapy (BCT) for patients undergoing breast-conserving therapy (BCT) to include lumpectomy with whole- surgery before or after neoadjuvant chemotherapy. breast irradiation is a practice supported by 6 prospective trials that Methods: There were 2983 patients who underwent segmental mastectomy demonstrated that overall survival is equivalent for patients undergo- with whole-breast irradiation from 1987 to 2005. Clinicopathological and 1–6 ing BCT versus mastectomy. Attention to margins was not standard outcome data were reviewed, and comparisons were made between those at the time these trials were conducted, and only the National Surgical undergoing surgery http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Surgery Wolters Kluwer Health

Impact of Chemotherapy Sequencing on Local-Regional Failure Risk in Breast Cancer Patients Undergoing Breast-Conserving Therapy

Annals of Surgery , Volume 257 (2) – Feb 1, 2013

Loading next page...
 
/lp/wolters-kluwer-health/impact-of-chemotherapy-sequencing-on-local-regional-failure-risk-in-LvBXkeGyH3

References (28)

Copyright
© 2013 by Lippincott Williams & Wilkins
ISSN
0003-4932
eISSN
1528-1140
DOI
10.1097/SLA.0b013e3182805c4a
pmid
23291658
Publisher site
See Article on Publisher Site

Abstract

FEATURE Impact of Chemotherapy Sequencing on Local-Regional Failure Risk in Breast Cancer Patients Undergoing Breast-Conserving Therapy ∗ ∗ Elizabeth A. Mittendorf, MD, Thomas A. Buchholz, MD,† Susan L. Tucker, PhD,‡ Funda Meric-Bernstam, MD, ∗ ∗ ∗ Henry M. Kuerer, MD, PhD, Ana M. Gonzalez-Angulo, MD,§ Isabelle Bedrosian, MD, Gildy V. Babiera, MD, ∗ ∗ Karen Hoffman, MD,† Min Yi, MD, PhD, Merrick I. Ross, MD, Gabriel N. Hortobagyi, MD,† and Kelly K. Hunt, MD uring the past several decades, significant advances have been Objective: This study was performed to evaluate long-term local-regional D made in local-regional therapy for breast cancer. The use of control rates after breast-conserving therapy (BCT) for patients undergoing breast-conserving therapy (BCT) to include lumpectomy with whole- surgery before or after neoadjuvant chemotherapy. breast irradiation is a practice supported by 6 prospective trials that Methods: There were 2983 patients who underwent segmental mastectomy demonstrated that overall survival is equivalent for patients undergo- with whole-breast irradiation from 1987 to 2005. Clinicopathological and 1–6 ing BCT versus mastectomy. Attention to margins was not standard outcome data were reviewed, and comparisons were made between those at the time these trials were conducted, and only the National Surgical undergoing surgery

Journal

Annals of SurgeryWolters Kluwer Health

Published: Feb 1, 2013

There are no references for this article.